Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV

By sjmartinez • April 9, 2025

Daar ES, Orkin C, Sax PE, Hagins D, Pozniak A, Workowski K, Brinson C, Tiraboschi JM, Liu H, Deaton C, Cohen C, Madera S, Hindman JT, Ramgopal M. Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV. AIDS Res Ther. 2025 Apr 7;22(1):45. doi: 10.1186/s12981-025-00732-w. PMID: 40197415; PMCID: PMC11978100.

Tags: antiretroviral therapy, Bictegravir, body mass index, dolutegravir, glucose, Harbor UCLA, HIV-1, Infectious Diseases, Publications, Tenofovir alafenamide

Effect of colchicine on progression of known coronary atherosclerosis in patients with stable coronary artery disease: EKSTROM randomized placebo controlled trial

Budoff MJ, Bhandari M, Iskander B, Ghanem AK, Kinninger A, Stark J, Garikapati V, Chilukuri S, Hankil V, Krishnan S, Punnanithinont N, Ichikawa K, Kambalapalli[...]

Disease Modification and Progression in Pre-Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Workshop Report

Putcha N, Bhatt SP, Bon J, Christenson SA, Han MK, Krishnan JA, Martinez FJ, Casaburi R, Crapo JD, Curtis JL, Diette GB, Dransfield MT, Eakin[...]

Trimethylamine N-oxide and related metabolites may regulate DNA methylation and trigger cardiovascular disease

Ma J, Lai CQ, Li XS, Wang M, Wang Z, Yao J, Guo X, Taylor KD, Lee S, Tracy RP, Peter D, Liu Y, Rotter[...]